Intestinal Absorption of 47Ca in Elderly Patients with Osteoporosis, Paget’s Disease and Osteomalacia. Effects of Calcitonin, Oestrogen and Vitamin D2

Gerontology ◽  
1977 ◽  
Vol 23 (1) ◽  
pp. 31-36 ◽  
Author(s):  
M. Lender ◽  
E. Verner ◽  
H. Stankiewicz ◽  
J. Menczel
Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5774-5774 ◽  
Author(s):  
Fernando M Vargas Madueno ◽  
Amin Benyounes ◽  
Gentry King ◽  
Kuan-Hsiang Gary Huang ◽  
Gabor Varadi

Abstract Introduction: Skeletal related events (SRE) in multiple myeloma (MM) patients are associated with significant morbidity and mortality. Studies assessing the anti myeloma effect of statins in conjunction with chemotherapy have shown conflicting results with regards to overall survival or disease response. To our knowledge there have been no studies evaluating the effect of statins on SRE. Here we sought to assess the relationship between statin use and the presence of SRE. Methods: We retrospectively reviewed 101 patients seen at our institution between the years 2007-2012 who had a diagnosis of MM separating them in 2 groups, patients on statin therapy (n=50) and those without statin therapy (n=51). Statin use was considered if present prior to the occurrence of a SRE. SRE were defined as pathologic fractures, necessity for orthopedic intervention, radiation therapy or spinal cord compression. MM stage as per the International Staging System (ISS), as well as history of osteoporosis, malignancy, hypothyroidism, Paget's disease of the bone, alcohol abuse, smoking status, calcium-vitamin D, and bisphosphonate use were also recorded. Results: In our cohorts the prevalence of SRE was significantly lower in patients on statin medication when compared to statin naive patients, (36% vs. 58.8% respectively, p = 0.029, Fisher's exact test, Figure 1). No significant differences were noted between statin treated group and statin naive group in the following variable subgroups (Fisher's exact test): the history of smoking or alcohol abuse, the documented diagnosis of osteoporosis, coexistent malignancy, hypothyroidism, or Paget's disease of the bone, and the use of other medications including bisphosphonates or calcium - vitamin D supplementation. There were no significant differences in distribution of cancer staging (according to ISS) when we compared between statin use status (chi-square test for trend). Conclusion: The use of statins was associated with a decrease in the prevalence of SRE in patients with MM. This was found independent of disease stage, history of osteoporosis or second malignancy, and bisphosphonate use. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


1983 ◽  
Vol 64 (2) ◽  
pp. 65P-65P
Author(s):  
D.F. Guilland-Cumming ◽  
P.J. Lawson-Matthew ◽  
S.K. Johnson ◽  
D.J. Beard ◽  
A. Yates ◽  
...  

1985 ◽  
Vol 22 (4) ◽  
pp. 559-566 ◽  
Author(s):  
D. F. GUILLARD-CUMMING ◽  
D. J. BEARD ◽  
D. L. DOUGLAS ◽  
S. K. JOHNSON ◽  
P. J. LAWSON-MATTHEW ◽  
...  

2013 ◽  
Vol 57 (7) ◽  
pp. 509-512 ◽  
Author(s):  
Luiz Griz ◽  
Francisco Bandeira ◽  
Erik Trovão Diniz ◽  
Marcelo Cabral ◽  
Eduardo Freese

OBJECTIVE: To investigate if vitamin D deficiency is more prevalent in patients with Paget's disease of bone (PDB) than in age-matched controls. SUBJECTS AND METHODS: We measured serum 25-OHD in 28 untreated patients with PDB and two control groups: 284 elderly men from an ongoing cohort from our department, and 151 postmenopausal women seen in our outpatient clinic for routine medical evaluation. RESULTS: The mean ± SD serum 25-OHD was significantly lower in subjects with PDB (23.76 ± 6.29 ng/mL) than in the control groups of elderly men (27.86 ± 13.52 ng/mL) and postmenopausal women (30.30 ± 9.59 ng/mL), p = 0.015. The prevalence of vitamin D deficiency considering a cut-off point of serum 25-OHD < 30 ng/mL was 85.7% in patients with PDB, and in elderly men and postmenopausal women it was 66.7 % and 54.3%, respectively (p < 0.001). CONCLUSION: These results suggest a high prevalence of hypovitaminosis D in patients with Paget's disease living in the tropics.


2011 ◽  
Vol 119 (09) ◽  
pp. 519-524 ◽  
Author(s):  
S. Polyzos ◽  
A. Anastasilakis ◽  
P. Makras ◽  
E. Terpos

AbstractPaget’s disease of bone (PDB) is the second most common metabolic bone disease. Bisphosphonates (BPs) are currently the drugs of choice for PDB. PDB and osteomalacia are both common in the elderly. The concept of relative vitamin D deficiency in patients with PDB was suggested long ago, but it has not yet elucidated. Both diseases predispose to fractures, but their combined action to fragility has not been studied yet. The older BPs, mainly etidronate, further inhibit bone mineralization. Mineralization defects have also been described in patients with PDB treated with pamidronate. Moreover, hypocalcemia and secondary hyperparathyroidism after treatment with BPs have been described in PDB. Hypocalcemia seems to be more severe after treatment with the more potent, intravenous zoledronic acid, which is currently the treatment of choice for PDB. The counteracting hyperparathyroidism pathophysiologically intends to increase renal reabsorption of calcium and 1.25-dihydroxy vitamin D production and to stimulate osteoclasts in order to prevent long-term hypocalcemia. However, the effect of PTH on osteoclasts is, at least partly, restricted in patients taking BPs. Secondary hyperparathyroidism is a potentially detrimental condition, especially in patients already suffering from another bone disease. Serum calcium and vitamin D deficiency should be restored before BP treatment and calcium and vitamin D administration should be possibly continued for longer after achieving normocalcemia, which may shorten the duration of secondary hyperparathyroidism.Mineralization defects and hypocalcemia with secondary hyperparathyroidism have been described in patients with Paget’s disease of bone treated with bisphosphonates. Secondary hyperparathyroidism may be a potentially detrimental condition for patients with Paget’s disease of bone.


1989 ◽  
Vol 76 (s20) ◽  
pp. 18P-18P
Author(s):  
T J Hine ◽  
W H Taylor

The Lancet ◽  
1981 ◽  
Vol 317 (8224) ◽  
pp. 833-834 ◽  
Author(s):  
C. Nagant De Deuxchaisnes ◽  
C. Rombouts-Lindemans ◽  
J.P. Huaux ◽  
J.P. Devogelaer ◽  
H. Withofs ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document